A retrospective evaluation of side‐effects associated with the booster dose of Pfizer-BioNTech/BNT162b2 COVID‐19 vaccine among females in Eastern Province, Saudi Arabia

Hassan, Yousif A. M.; Ali, Mohammad Daud; Al-Eid, Rawan Rashad; Ghuraya, Fatimah Ali Al; Alqasimi, Zainab Essa; Ahmad, Ayaz; Eltrafi, Zainab; Ghosn, Sherihan Ahmad

doi:10.1016/j.vaccine.2022.10.009

Cited by 7 publications

(5 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study showed that the most frequent adverse effects were pain at the injection site, fatigue, muscle pain, swelling at the injection site, headache, fever and chills. These findings are in accordance with the literature regarding the adverse effects of the first booster dose [14–18,22,23]. Moreover, a recent systematic review investigated the prevalence of adverse effects after the primary COVID-19 vaccine doses and found that the most frequent adverse effects among 10,632 participants were pain at the injection site (77.3%), muscle pain (39.7%), swelling at the injection site (34%), headache (33.3%), chills (18.3%), fever (18%), swollen lymph nodes (8%), nausea (7.9%), and shortness of breath (7.6%) [11].…”

Section: Discussionsupporting

confidence: 93%

“…Literature supports this finding since two other studies found that all participants had adverse effects after the first booster dose [20,21]. Other studies found also high prevalence of adverse effect after the first booster dose ranging from 74.7% to 89% [14][15][16][17]22,23]. Slight differences in prevalence of adverse effects among studies could be attributed to different study designs, populations, and definitions.…”

Section: (Which Was Not Certified By Peer Review)mentioning

confidence: 79%

See 1 more Smart Citation

Prevalence and risk factors of adverse effects after the first COVID-19 booster dose: evidence from Greece

Galanis

Katsiroumpa

Vraka

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: In general, COVID-19 vaccines are safe and effective, but minor adverse effects are common. Objective: To estimate the prevalence of adverse effects after the first COVID-19 booster dose, and to identify possible risk factors. Material and methods: We conducted a cross-sectional study with a convenience sample in Greece during November 2022. We measured several adverse effects after the booster dose, such as pain at the injection site, swelling at the injection site, fatigue, muscle pain, headaches, fever, chills, nausea, etc. We considered gender, age, chronic disease, self-assessment of health status, COVID-19 diagnosis, and self-assessment of COVID-19 course as possible predictors of adverse effects. Results: In our sample, 96% developed at least one adverse effect. Half of the participants (50.2%) developed one to five adverse effects, 35.9% developed six to ten adverse effects, and 9.5% developed 11 to 16 adverse effects. Mean number of adverse effects was 5.5. The most frequent adverse effects were pain at the injection site (84.3%), fatigue (70.8%), muscle pain (61%), swelling at the injection site (55.2%), headache (49.8%), fever (42.9%), and chills (41%). Females developed more adverse effects than males (p<0.001). Also, we found a positive relationship between severity of COVID-19 symptoms and adverse effects of COVID-19 vaccines (p=0.005). Moreover, younger age was associated with increased adverse effects (p<0.001). Conclusions: Almost all participants in our study developed minor adverse effects after the booster dose. Female gender, worse clinical course of COVID-19, and decreased age were associated with increased adverse effects.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: (Which Was Not Certified By Peer Review)mentioning

confidence: 79%

Prevalence and risk factors of adverse effects after the first COVID-19 booster dose: evidence from Greece

Galanis

Katsiroumpa

Vraka

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…As far as we known, vaccination triggers the necessary immune response. The immune activation may temporarily interfere with the HPO axis [ 56 ]. In addition, cyclic breakdown and restoration of the uterine endometrium are mediated by immune cells residing in the endometrium [ 57 ].…”

Section: Covid-19 Vaccination and Female Reproductive Healthmentioning

confidence: 99%

Female reproductive health during the COVID-19 pandemic: latest evidence and understanding

Liu

et al. 2023

Arch Gynecol Obstet

View full text Add to dashboard Cite

Purpose The ongoing coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has imposed a heavy burden on medical systems. In addition to the respiratory system, the virus also causes injuries to other organs and systems such as the gastroenteric system, kidneys, and reproductive system. Female reproductive health requires more attention in this context. Methods We have performed a thorough review of the relevant literature that addresses the impacts of SARS-CoV-2 infection and COVID-19 vaccination on the female reproductive system. Results Most evidence shows that SARS-CoV-2 does not infect the female reproductive system. However, the virus may indirectly influence sex hormone concentrations through inflammation associated with cytokine storms and nervous system damage. Menstrual disorders in women infected with SARS-CoV-2 may be caused by down-regulation of angiotensin-converting enzyme 2, abnormal hormone levels, medications, and stress. There is no significant difference in ovarian follicle quality and in vitro fertilization parameters between the pre- and post-COVID-19 vaccination groups. In addition, most symptoms due to side effects of vaccination could recover within a short period of time. Conclusion SARS-CoV-2 infection affects female reproductive system function through multiple mechanisms. It is recommended that women of childbearing age be vaccinated with COVID-19 vaccine.

show abstract

“…4 A small number of significant adverse effects were reported following the Pfizer-BioNTech BNT162b2 vaccination against corona virus disease 2019 (COVID-19). [5][6][7] Most of the Israeli population received at least three doses of the Pfizer-BioNTech BNT162b2 vaccination. We found a higher incidence of myocarditis in young males who had received Pfizer-BioNTech BNT162b2 vaccinations as compared to historical controls and unvaccinated individuals.…”

Section: Introductionmentioning

confidence: 99%

“…It was reported that the risk of developing myocarditis was increased in hospitalized COVID‐19 patients compared to non‐COVID‐19 patients 4 . A small number of significant adverse effects were reported following the Pfizer‐BioNTech BNT162b2 vaccination against corona virus disease 2019 (COVID‐19) 5–7 …”

Section: Introductionmentioning

confidence: 99%

HLA binding‐groove motifs are associated with myocarditis induction after Pfizer‐BioNTech BNT162b2 vaccination

Aharon,

Benedek,

Barhoum

et al. 2023

Eur J Clin Investigation

View full text Add to dashboard Cite

Background and AimsWe found a higher incidence of myocarditis in young males who had received at least two Pfizer‐BioNTech BNT162b2 vaccinations. The human leukocyte antigens (HLA) are known to play an important role in infectious and autoinflammatory diseases. We hypothesized that certain HLA alleles might be associated with vaccination‐induced myocarditis.MethodsHLA typing was performed using next‐generation sequencing technology with the Illumina Iseq100 platform. HLA class I and II loci were genotyped in 29 patients with post‐vaccination myocarditis and compared with HLA data from 300 healthy controls.ResultsWe demonstrate that the DRB1*14:01, DRB1*15:03 alleles and the motifs in HLA‐A − Leu62 and Gln63, which are part of binding pocket B and HLA‐DR Tyr47, His60, Arg70 and Glu74, which are part of binding pockets P4, P7 and P9, were significantly associated with disease susceptibility.ConclusionsOur findings suggest that immunogenetic fingerprints in HLA peptide‐binding grooves may affect the presentation of peptides derived from the Pfizer‐BioNTech BNT162b2 vaccination to T cells and induce an inflammatory process that results in myocarditis.

show abstract

A retrospective evaluation of side‐effects associated with the booster dose of Pfizer-BioNTech/BNT162b2 COVID‐19 vaccine among females in Eastern Province, Saudi Arabia

Cited by 7 publications

References 43 publications

Prevalence and risk factors of adverse effects after the first COVID-19 booster dose: evidence from Greece

Prevalence and risk factors of adverse effects after the first COVID-19 booster dose: evidence from Greece

Female reproductive health during the COVID-19 pandemic: latest evidence and understanding

HLA binding‐groove motifs are associated with myocarditis induction after Pfizer‐BioNTech BNT162b2 vaccination

Contact Info

Product

Resources

About